Reply  by Roldan, Carlos A. & Crawford, Michael
JACC Vol . 22 . No. 4
October 1993.1268-71
Antiphospholipid Antibodies and Valve
Disease in Patients With Systemic
Lupus Erythematosus
Roldan et al . (l) are to he congratulated on their study of heart valve
disease in patients with systemic lupus erythematosus . The large
number of patients involved and their use of high resolution trans-
esophageal echocardiography to detect valve abnormalities make
this an important contribution . However, several methodologic
considerations limit the ability to draw conclusions regarding the
possible pathogenic role of antiphospholipid antibodies in the devel-
opment of heart valve disease in the study patients .
1 . The authors compared the prevalence of heart valve disease
between the total of patients with systemic lupus erythematosus
who test positive for antiphospholipid antibodies (Group 1) and
those who test negative (Group 11) without taking into accuunt the
level of positivity . They concluded that there was no apparent
justification for considering antiphospholipid antibodies to be a risk
factor for heart valve disease in these patients . The Second Inter-
national Anticardiolipin Standardization Workshop recommended
that only moderately and highly positive serum values be considered
clinically relevant (2). Thus, Roldan et al . may have diluted their
antibody-positive group of patients with low risk patients . How
many of their 22 patients with lupus and positive antiphospholipid
antibodies had moderate to high serum levels? Of those with
moderate to high levels, how many had significant heart valve
disease? With the use of two-dimensional transthoracic echocardi-
ography in our own prospective studies (3,4) and in those of other
investigators (5-7), a statistically significant association was found
between antiphospholipid antibodies and heart valve disease, both
in patients with systemic lupus erythematosus and in those with the
primary antiphospholipid syndrome .
2 . The authors did not provide details of the methods used to
measure antiphospholipid antibodies in their study . It was recently
suggested (8,9) that antiphospholipid antibodies in autoimmune
diseases require a cofactor for maximal binding to cardiolipin in the
enzyme-linked immunoabsorbenl assay (ELISA) system . This co-
factor has been identified as beta-2 glycoprotein I (apolipoprotein
H), a normal plasma protein with a serum concentration of
-200 pg/ml (9) . The use of 10% adult or fetal bovine serum in
phosphate-buffered saline solution as diluent for the test serum
would provide enough cofactor for anticardiolipin antibodies to have
maximal binding (10) . This fundamental technical issue should be
clarified before final conclusions can be drawn from this study .
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Reply
Khamashta and Hughes raise two important issues regarding our
study of valve disease in patients with systemic lupus erythemato-
sus. The first concerns the antiphospholipid antibody measurement
technique.
The IgG and 1gM anticardiolipin antibodies were measured by a
standardized enzymatic immunosorbent assay (ELISA) using 10%
adult bovine serum as a diluent and expressed in international units
(IU) (1,2) .
The second concerns the relation between the level of anticar-
diolipin antibody positivity versus the incidence of valve disease .
The IgG positivity was categorized as: absent = <8 IU, I+
positive = 8 to 19 LU, 2+ positive = 20 to 49 IU, 3+ positive = 50
to 79 IU, 4+ positive = >80 IU . For IgM, absent = <10 IU, I+
positive = 10 to 19 IU, 2+ positive = 20 to 29 IU, 3+ positive = 30
to 591U, and 4 r positive = >60 I(.' . Nineteen patients with lupus
and nine patients with antiphospholipid syndrome had IgG or 1gM
anticardiolipin antibodies, or both . The mean concentration of IgG
and 1gM antibodies in the two groups was similar : 59 ± 61 IU and 34
24 IU and 65 ± 35 IU and 40 ± 22 LU, respectively . There was no
association between the highest positivity level of either igG or 1gM
antibodies and the frequency of valve abnormalities in both groups
(Table 1).
Table 1. Correlation of Antibody (AB) Positivity and Valve
Disease (VD) in Patients With Systemic Lupus Erytheinatosus
(SLE) or Antiphospholipid Syndrome (APS)
AB Positivity
SLE +AB
(VD/n)
APS
(VD/n)
1+ 416
1/2
2+ 415
0 /(1
3+
3/4 2/3
4+
414
014
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The major issue raised by these questions is whether antiphos-
pholipid antibodies are related to valve disease in patients with lupus
erythematosus or antiphospholipid syndrome
. Khamashta et al
. (3),
studied 132 patients with lupus by transthoracic echocardiography
and found valve disease in 30 (23%), valve vegetations in 9 and
mitral regurgitation by continuous wave Doppler study in 21
. Fifty
patients (38%) had either anticardiolipin antibodies (84%) or lupus
anticoagulant (16%)
. Of those with anticardiolipin antibodies, 38%
to 50% had low levels of either IgG or IgM immunogtobulin antibodies
.
Furthermore, 33% of patients with valve vegetations and 52% of those
with mitral regurgitation had absent or low levels of antibodies
. Thus,
it could be argued that their data did not establish a causal relation
between anticandiolipin antibodies and valve disease
.
Calve et al, (4) studied 25 patients with lupus by transthoracic
echocardiography and found valve disease in 9 (36%)
. Eight (89%) of
these nine had anticardiolipin antibodies, 59
t 44 IU for ISO and
13 t 14 IU for ISMM
. Seven (44%) of 16 patients with normal valves
had 40 or ISM anticardiolipin antibodies (48
t
51 IU and 7 t 5 IU
.
respectively), When both groups were compared, no difference was
found in the frequency and concentration of antibodies (p = 0
.55) .
The level of antibody positivity in relation w valve disease was not
given
. The investigators conclude that an association between
antiphospholipid antibodies and systemic lupus erythematosus
valve disease may exist but does not necessarily indicate a causal
relation.
Nihoyannopoulos et al . (5) found cardiac disease by trans-
thoracic echocardiography in 50 (54%) of 94 patients with lupus
. Of
these 50 patients, 39 (78%) had IgG or ISM anticardiolipin antibod-
ies, however, only 7 (18%) of them had very high levels (>100 U)
and 43 (82%) had a wide range of positivity (9 to 100 U) . The
majority (72%) of patir 's with cardiac disease were in this last
group, but no mention is made of the low positivity level and
cardiac abnormalities . Furthermore, 26% of patients without
antibodies had cardiac abnormalities and 23% with high levels
had a normal heart . The investigators concluded that this associa-
tion may suggest a causal relation, but their results do not establish
this linnk.
Calve et al . (6). in 28 patients with primary antiphospholipid
syndrome found valve disease by transthoracic echocardiography in
10 (36%). No difference was found in the concentration of IgG
anticandidipin antibody between patients with abnormal or normal
valves (91 t 132 IU and 60 ± 54 IU, respectively ; p > 0.2).
They
concluded that their study did not elucidate a causal relation
between antiphospholipid antibodies and valve disease in the pri-
mary antiphosphoipid syndrome .
Finally
. Li et al . (7) studied 50 patients with lupus by trans-
thoracic echocardiography and found valve regurgitation in up to
68% of them. Thirty patients (64%) had ISO or ISM anticardiolipin
antibodies
. However, no association was found between the pres-
ent
: or severity of valve lesions and the presence of antibodies (p >
0.2). Similarly, in our study, which used transesophageal echocar
. ,
diography, there was no difference in the frequency of valve disease
between the patients with lupus who had (77%) or did not have
(72%) antiphospholipid antibodies
.
Thus, we believe that the pathogenesis of systemic lupus erythe-
matosus valve disease is still unknown and our results and those of
others do not support the hypothesis that wttiphosphoipid antibod-
ies are a primary pathogenetic or risk factor
.
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assessing Collateral Development After
Acute Myocardial Infarction
Fujita et al . (1) using quantitative coronary angiography demon-
strated in seven patients an increase in collateral circulation to an
occluded infarct-related artery on serial angiograpby between day I
and 6 weeks later. Their novel approach to assessment of collateral
circulation was based on the mealsureav nt of the proximal diameter
of the recipient vessel and demonstration of an increase in that
measurement from day I to 6 weeks while there was no change in
the measurements of the donor vessel .
The results and conclusions of this study rest on the measure-
ment of the recipient vessel diameter and, more precisely, on the
amount of contrast material within the lumen . Several important
technical and methodologic aspects were not reported: 1) Was the
assessment of paired angiograms blinded? 2) What was the power
and rate of contrast material injection into the donor vessel because
this clearly would determine the amount of contrast material appear-
ing in the recipient vessel? 3) How long was the cineangiogram taken
for in filming the filling of the recipient vessel and how long after the
injection of the donor vessel was the measurement of the diameter of
the recipient vessel performed because these would also affect the
amount of contrast material within the lumen? 4) Was the first
injection of the donor vessel used for analysis? If not, an accumu-
lation of contrast material in background tissues could have added
error to the subsequent measurements . 5) We are told that the
recipient vessel was measured at the proximal point; however, that
point was not precisely the same between day I and 6 weeks . A
more proximal measurement could be responsible for difference in
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